Merck Hosts Investor Event Highlighting CV Portfolio and Pipeline
Yesterday, Merck hosted an investor event (view presentation replay; view slides; view fact sheet) providing an overview of the company’s CV portfolio and pipeline. During the event, Merck highlighted eight potential new approvals across its CV pipeline, including its ongoing late-stage clinical programs in ASCVD, HF, PAH, thrombosis, and ESRD. In particular, Merck discussed its oral PCSK9i (MK-0616), currently in Ph2 development for hypercholesterolemia, as well as vericiguat (Verquvo) for symptomatic chronic HF. Below, FENIX provides highlights and insight from the call, including thoughts on Merck’s seemingly renewed focus on its CV business.
About The Author
Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.
If you receive our email blasts, you already have an account. Log in now
You can read the article’s full content online after purchase.